Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 21, 2017
Which drugs does patent 6,667,314 protect, and when does it expire?
| Title: | Tropane derivatives useful in therapy |
| Abstract: | The present invention provides compounds of the formula: ##STR1## wherein R.sup.1 is C.sub.3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or C.sub.3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R.sup.2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds. |
| Inventor(s): | Perros; Manoussos (County of Kent, GB), Price; David Anthony (County of Kent, GB), Stammen; Blanda Luzia Christa (County of Kent, GB), Wood; Anthony (County of Kent, GB) |
| Assignee: | Pfizer, Inc. (New York, NY) |
| Application Number: | 09/865,950 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Process; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-003 | Nov 4, 2016 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | ||
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-004 | Nov 4, 2016 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | ||
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-001 | Aug 6, 2007 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | ||
Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-002 | Aug 6, 2007 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | ||
Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | ||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0015835 | Jun 27, 2000 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,368,460 | Tropane derivatives useful in therapy | ► Subscribe | |||||||||||||
| 7,576,097 | Tropane derivatives useful in therapy | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1965 | ► Subscribe | |||||||||||||
| African Regional IP Organization (ARIPO) | 200202663 | ► Subscribe | |||||||||||||
| Argentina | 028622 | ► Subscribe | |||||||||||||
| Argentina | 060159 | ► Subscribe | |||||||||||||
| Austria | 260914 | ► Subscribe | |||||||||||||
| Austria | 407134 | ► Subscribe | |||||||||||||
| Australia | 2001252482 | ► Subscribe | |||||||||||||
| Australia | 5248201 | ► Subscribe | |||||||||||||
| Bulgaria | 107140 | ► Subscribe | |||||||||||||
| Bulgaria | 65966 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,968 others who get our Drug Patent Expiration Alerts:
